Mycophenolic acid (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Mycophenolic acid" in English language version.

refsWebsite

Global rank English rank

39nih.gov

4^th place

32doi.org

2^nd place

25web.archive.org

1^st place

15semanticscholar.org

11^th place

8^th place

4books.google.com

3^rd place

4fda.gov

447^th place

338^th place

3drugs.com

399^th place

333^rd place

3medicines.org.uk

3,823^rd place

2,387^th place

3harvard.edu

18^th place

17^th place

2clincalc.com

3,912^th place

2,496^th place

2tga.gov.au

3,984^th place

2,622^nd place

1guildlink.com.au

low place

1europa.eu

68^th place

117^th place

1psu.edu

207^th place

136^th place

1medscape.com

719^th place

636^th place

1bnf.org

low place

1newsinferno.com

low place

1archive.org

6^th place

1unc.edu

1,538^th place

1,042^nd place

1handle.net

102^nd place

76^th place

1stanford.edu

179^th place

183^rd place

1roche.com

low place

archive.org

Parnham FP, Nijkamp MJ, eds. (2005). Principles of immunopharmacology (2nd rev. and extended ed.). Basel: Birkhèauser Verlag. p. 453. ISBN 978-3764358044.

bnf.org

"Homepage - BNF Publications". www.bnf.org. Archived from the original on 27 April 2021. Retrieved 9 November 2014.

books.google.com

Schiff ER, Maddrey WC, Sorrell MF (2011). Schiff's Diseases of the Liver. John Wiley & Sons. p. PT3219. ISBN 978-1-119-95048-6. Archived from the original on 29 April 2023. Retrieved 23 September 2020.
Laskin AI, Bennett JW, Gadd GM (2001). Advances in Applied Microbiology. Gulf Professional Publishing. p. 236. ISBN 978-0-12-002648-7. Archived from the original on 29 April 2023. Retrieved 23 September 2020.
Harber M (2014). Harber M (ed.). Practical nephrology. Springer. p. 449. ISBN 978-1-4471-5547-8. Archived from the original on 29 April 2023. Retrieved 23 September 2020.
Zhang L, Demain AL (2005). Natural Products: Drug Discovery and Therapeutic Medicine. Totowa, N.J.: Humana Press. p. 14. ISBN 978-1-59259-976-9. Archived from the original on 29 April 2023. Retrieved 16 August 2019.

clincalc.com

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Mycophenolate Mofetil Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

doi.org

D'Cruz DP, Khamashta MA, Hughes GR (February 2007). "Systemic lupus erythematosus". Lancet. 369 (9561): 587–96. CiteSeerX 10.1.1.1008.5428. doi:10.1016/S0140-6736(07)60279-7. PMID 17307106. S2CID 28468112.
Moore RA, Derry S (2006). "Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis". Arthritis Research & Therapy. 8 (6): R182. doi:10.1186/ar2093. PMC 1794528. PMID 17163990.
Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL (September 1997). "Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses". Journal of the American Academy of Dermatology. 37 (3 Pt 1): 445–9. doi:10.1016/S0190-9622(97)70147-6. PMID 9308561.
Singh JA, Hossain A, Kotb A, Wells GA (September 2016). "Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis". Systematic Reviews. 5 (1): 155. doi:10.1186/s13643-016-0328-z. PMC 5020478. PMID 27619512.
Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR (September 2007). "Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis". Clinical Journal of the American Society of Nephrology. 2 (5): 968–75. doi:10.2215/CJN.01200307. PMID 17702723.
Knight SR, Russell NK, Barcena L, Morris PJ (March 2009). "Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review". Transplantation. 87 (6): 785–94. doi:10.1097/TP.0b013e3181952623. PMID 19300178. S2CID 33596652.
Remuzzi G, Lesti M, Gotti E, Ganeva M, Dimitrov BD, Ene-Iordache B, et al. (2004). "Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial". Lancet. 364 (9433): 503–12. doi:10.1016/S0140-6736(04)16808-6. PMID 15302193. S2CID 22033113.
Fu R, Ceballos-Picot I, Torres RJ, Larovere LE, Yamada Y, Nguyen KV, et al. (May 2014). "Genotype-phenotype correlations in neurogenetics: Lesch-Nyhan disease as a model disorder". Brain. 137 (Pt 5): 1282–303. doi:10.1093/brain/awt202. PMC 3999711. PMID 23975452.
Anderson HA, Bracewell JM, Fraser AR, Jones D, Robertson GW, Russell JD (December 1988). "5-Hydroxymaltol and mycophenolic acid, secondary metabolites from Penicillium echinulatum". Transactions of the British Mycological Society. 91 (4): 649–651. doi:10.1016/S0007-1536(88)80040-8.
Fulton B, Markham A (February 1996). "Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation". Drugs. 51 (2): 278–98. doi:10.2165/00003495-199651020-00007. PMID 8808168. S2CID 46954073.
Ransom JT (December 1995). "Mechanism of action of mycophenolate mofetil". Therapeutic Drug Monitoring. 17 (6): 681–4. doi:10.1097/00007691-199512000-00023. PMID 8588241. S2CID 6439393.
Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. (November 2011). "Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis". The New England Journal of Medicine. 365 (20): 1886–95. doi:10.1056/NEJMoa1014460. hdl:20.500.12648/8250. PMID 22087680. S2CID 27689350. Archived from the original on 8 March 2022. Retrieved 25 November 2021.
Zhang W, Ding C, Zheng S (April 2014). "Enteric-coated mycophenolate sodium: an update". International Journal of Clinical Practice. Supplement. 68 (181): 1–3. doi:10.1111/ijcp.12399. PMID 24673712. S2CID 2630344.
Lipsky JJ (November 1996). "Mycophenolate mofetil". Lancet. 348 (9038): 1357–9. doi:10.1016/S0140-6736(96)10310-X. PMID 8918281. S2CID 36837474.
Regueira TB, Kildegaard KR, Hansen BG, Mortensen UH, Hertweck C, Nielsen J (May 2011). "Molecular basis for mycophenolic acid biosynthesis in Penicillium brevicompactum". Applied and Environmental Microbiology. 77 (9): 3035–43. Bibcode:2011ApEnM..77.3035R. doi:10.1128/AEM.03015-10. PMC 3126426. PMID 21398490.
Bentley R (October 2000). "Mycophenolic Acid: a one hundred year odyssey from antibiotic to immunosuppressant". Chemical Reviews. 100 (10): 3801–26. doi:10.1021/cr990097b. PMID 11749328.
Watts G (2014). "Anthony Clifford Allison". The Lancet. 383 (9925): 1290. doi:10.1016/S0140-6736(14)60635-8. S2CID 54281245.
Allison AC (May 2000). "Immunosuppressive drugs: the first 50 years and a glance forward". Immunopharmacology. 47 (2–3): 63–83. doi:10.1016/S0162-3109(00)00186-7. PMID 10878284.
Allison AC, Kowalski WJ, Muller CD, Eugui EM (November 1993). "Mechanisms of action of mycophenolic acid". Annals of the New York Academy of Sciences. 696 (1): 63–87. Bibcode:1993NYASA.696...63A. doi:10.1111/j.1749-6632.1993.tb17143.x. PMID 7906496. S2CID 34520788.
Nelson PH, Eugui E, Wang CC, Allison AC (February 1990). "Synthesis and immunosuppressive activity of some side-chain variants of mycophenolic acid". Journal of Medicinal Chemistry. 33 (2): 833–8. doi:10.1021/jm00164a057. PMID 1967654.
Eugui EM, Allison AC (June 1993). "Immunosuppressive activity of mycophenolate mofetil". Annals of the New York Academy of Sciences. 685 (1): 309–29. Bibcode:1993NYASA.685..309E. doi:10.1111/j.1749-6632.1993.tb35881.x. PMID 8363235. S2CID 9028169.
Allison AC, Eugui EM (February 1996). "Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF)". Clinical Transplantation. 10 (1 Pt 2): 77–84. doi:10.1111/j.1399-0012.1996.tb00651.x. PMID 8680053.
Allison AC, Eugui EM (1993). "The design and development of an immunosuppressive drug, mycophenolate mofetil". Springer Seminars in Immunopathology. 14 (4): 353–80. doi:10.1007/bf00192309. PMID 8322167. S2CID 26433174.
Allison AC, Eugui EM (December 1993). "Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil". Immunological Reviews. 136 (1): 5–28. doi:10.1111/j.1600-065x.1993.tb00652.x. PMID 7907572. S2CID 711727.
Bechstein WO, Suzuki Y, Kawamura T, Jaffee B, Allison A, Hullett DA, et al. (1992). "Low-dose combination therapy of DUP-785 and RS-61443 prolongs cardiac allograft survival in rats". Transplant International. 5 (Suppl 1): S482-3. doi:10.1111/tri.1992.5.s1.482. PMID 14621853. S2CID 222199749.
Kawamura T, Hullett DA, Suzuki Y, Bechstein WO, Allison AM, Sollinger HW (April 1993). "Enhancement of allograft survival by combination RS-61443 and DUP-785 therapy". Transplantation. 55 (4): 691–4, discussion 694–5. doi:10.1097/00007890-199304000-00001. PMID 8475537.
van Gelder T, Hesselink DA (May 2015). "Mycophenolate revisited". Transplant International. 28 (5): 508–15. doi:10.1111/tri.12554. PMID 25758949. S2CID 1673466.
Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC (June 2003). "Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil". Archives of Dermatology. 139 (6): 739–42. doi:10.1001/archderm.139.6.739. PMID 12810504.
Diamond MS, Zachariah M, Harris E (December 2002). "Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA". Virology. 304 (2): 211–21. doi:10.1006/viro.2002.1685. PMID 12504563.
Takhampunya R, Ubol S, Houng HS, Cameron CE, Padmanabhan R (July 2006). "Inhibition of dengue virus replication by mycophenolic acid and ribavirin". The Journal of General Virology. 87 (Pt 7): 1947–52. doi:10.1099/vir.0.81655-0. PMID 16760396.
Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, et al. (December 2013). "Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus". The Journal of Infection. 67 (6): 606–16. doi:10.1016/j.jinf.2013.09.029. PMC 7112612. PMID 24096239.
Xiao Y, Huang J, Luo H, Wang J (February 2014). "Mycophenolate mofetil for relapsing-remitting multiple sclerosis". The Cochrane Database of Systematic Reviews. 2014 (2): CD010242. doi:10.1002/14651858.CD010242.pub2. PMC 10875409. PMID 24505016.

drugs.com

"Mycophenolate mofetil (CellCept) Use During Pregnancy". Drugs.com. 24 January 2020. Archived from the original on 28 October 2019. Retrieved 6 April 2020.
"Mycophenolate Monograph for Professionals". Drugs.com. Archived from the original on 21 April 2020. Retrieved 28 October 2019.
Drugs.com: Mycophenolic acid Side Effects

europa.eu

ema.europa.eu

"CellCept EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 6 April 2020. Retrieved 6 April 2020.

fda.gov

"CellCept (mycophenolate mofetil) August 2009". U.S. Food and Drug Administration. 14 August 2009. Archived from the original on 21 August 2009. Retrieved 21 August 2009.
"CellCept (mycophenolate mofetil) August 2009". U.S. Food and Drug Administration. 14 August 2009. Archived from the original on 21 August 2009. Retrieved 21 August 2009.
"MedWatch Safety Alerts for Human Medical Products". fda.gov. May 2008. Archived from the original on 19 October 2010. Retrieved 26 October 2010.
"Risk Evaluation and Mitigation Strategy (REMS) Under Review for CellCept and Myfortic". U.S. Food and Drug Administration. Archived from the original on 8 August 2014. Retrieved 23 July 2014.

guildlink.com.au

"CellCept (mycophenolate mofetil)". Australian Product Information. 30 November 2021. Archived from the original on 8 January 2023. Retrieved 8 January 2023.

handle.net

hdl.handle.net

Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. (November 2011). "Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis". The New England Journal of Medicine. 365 (20): 1886–95. doi:10.1056/NEJMoa1014460. hdl:20.500.12648/8250. PMID 22087680. S2CID 27689350. Archived from the original on 8 March 2022. Retrieved 25 November 2021.

harvard.edu

ui.adsabs.harvard.edu

Regueira TB, Kildegaard KR, Hansen BG, Mortensen UH, Hertweck C, Nielsen J (May 2011). "Molecular basis for mycophenolic acid biosynthesis in Penicillium brevicompactum". Applied and Environmental Microbiology. 77 (9): 3035–43. Bibcode:2011ApEnM..77.3035R. doi:10.1128/AEM.03015-10. PMC 3126426. PMID 21398490.
Allison AC, Kowalski WJ, Muller CD, Eugui EM (November 1993). "Mechanisms of action of mycophenolic acid". Annals of the New York Academy of Sciences. 696 (1): 63–87. Bibcode:1993NYASA.696...63A. doi:10.1111/j.1749-6632.1993.tb17143.x. PMID 7906496. S2CID 34520788.
Eugui EM, Allison AC (June 1993). "Immunosuppressive activity of mycophenolate mofetil". Annals of the New York Academy of Sciences. 685 (1): 309–29. Bibcode:1993NYASA.685..309E. doi:10.1111/j.1749-6632.1993.tb35881.x. PMID 8363235. S2CID 9028169.

medicines.org.uk

"CellCept 1g/5ml powder for oral suspension - Summary of Product Characteristics (SmPC)". (emc). 27 February 2020. Archived from the original on 25 September 2020. Retrieved 22 October 2020.
"Cellcept 250mg Capsules - Summary of Product Characteristics (SmPC)". (emc). 17 June 2020. Archived from the original on 25 September 2020. Retrieved 22 October 2020.
"Cellcept 500mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 25 September 2020. Retrieved 22 October 2020.

medscape.com

reference.medscape.com

"CellCept, Myfortic (mycophenolate) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Archived from the original on 30 April 2021. Retrieved 9 November 2014.

newsinferno.com

"FDA Issues Second CellCept Warning". newsinferno.com. 18 May 2008. Archived from the original on 24 February 2013. Retrieved 26 October 2010.

nih.gov

pubmed.ncbi.nlm.nih.gov

D'Cruz DP, Khamashta MA, Hughes GR (February 2007). "Systemic lupus erythematosus". Lancet. 369 (9561): 587–96. CiteSeerX 10.1.1.1008.5428. doi:10.1016/S0140-6736(07)60279-7. PMID 17307106. S2CID 28468112.
Moore RA, Derry S (2006). "Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis". Arthritis Research & Therapy. 8 (6): R182. doi:10.1186/ar2093. PMC 1794528. PMID 17163990.
Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL (September 1997). "Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses". Journal of the American Academy of Dermatology. 37 (3 Pt 1): 445–9. doi:10.1016/S0190-9622(97)70147-6. PMID 9308561.
Singh JA, Hossain A, Kotb A, Wells GA (September 2016). "Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis". Systematic Reviews. 5 (1): 155. doi:10.1186/s13643-016-0328-z. PMC 5020478. PMID 27619512.
Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR (September 2007). "Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis". Clinical Journal of the American Society of Nephrology. 2 (5): 968–75. doi:10.2215/CJN.01200307. PMID 17702723.
Knight SR, Russell NK, Barcena L, Morris PJ (March 2009). "Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review". Transplantation. 87 (6): 785–94. doi:10.1097/TP.0b013e3181952623. PMID 19300178. S2CID 33596652.
Remuzzi G, Lesti M, Gotti E, Ganeva M, Dimitrov BD, Ene-Iordache B, et al. (2004). "Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial". Lancet. 364 (9433): 503–12. doi:10.1016/S0140-6736(04)16808-6. PMID 15302193. S2CID 22033113.
Fu R, Ceballos-Picot I, Torres RJ, Larovere LE, Yamada Y, Nguyen KV, et al. (May 2014). "Genotype-phenotype correlations in neurogenetics: Lesch-Nyhan disease as a model disorder". Brain. 137 (Pt 5): 1282–303. doi:10.1093/brain/awt202. PMC 3999711. PMID 23975452.
Fulton B, Markham A (February 1996). "Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation". Drugs. 51 (2): 278–98. doi:10.2165/00003495-199651020-00007. PMID 8808168. S2CID 46954073.
Ransom JT (December 1995). "Mechanism of action of mycophenolate mofetil". Therapeutic Drug Monitoring. 17 (6): 681–4. doi:10.1097/00007691-199512000-00023. PMID 8588241. S2CID 6439393.
Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. (November 2011). "Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis". The New England Journal of Medicine. 365 (20): 1886–95. doi:10.1056/NEJMoa1014460. hdl:20.500.12648/8250. PMID 22087680. S2CID 27689350. Archived from the original on 8 March 2022. Retrieved 25 November 2021.
Zhang W, Ding C, Zheng S (April 2014). "Enteric-coated mycophenolate sodium: an update". International Journal of Clinical Practice. Supplement. 68 (181): 1–3. doi:10.1111/ijcp.12399. PMID 24673712. S2CID 2630344.
Lipsky JJ (November 1996). "Mycophenolate mofetil". Lancet. 348 (9038): 1357–9. doi:10.1016/S0140-6736(96)10310-X. PMID 8918281. S2CID 36837474.
Regueira TB, Kildegaard KR, Hansen BG, Mortensen UH, Hertweck C, Nielsen J (May 2011). "Molecular basis for mycophenolic acid biosynthesis in Penicillium brevicompactum". Applied and Environmental Microbiology. 77 (9): 3035–43. Bibcode:2011ApEnM..77.3035R. doi:10.1128/AEM.03015-10. PMC 3126426. PMID 21398490.
Bentley R (October 2000). "Mycophenolic Acid: a one hundred year odyssey from antibiotic to immunosuppressant". Chemical Reviews. 100 (10): 3801–26. doi:10.1021/cr990097b. PMID 11749328.
Allison AC (May 2000). "Immunosuppressive drugs: the first 50 years and a glance forward". Immunopharmacology. 47 (2–3): 63–83. doi:10.1016/S0162-3109(00)00186-7. PMID 10878284.
Allison AC, Kowalski WJ, Muller CD, Eugui EM (November 1993). "Mechanisms of action of mycophenolic acid". Annals of the New York Academy of Sciences. 696 (1): 63–87. Bibcode:1993NYASA.696...63A. doi:10.1111/j.1749-6632.1993.tb17143.x. PMID 7906496. S2CID 34520788.
Nelson PH, Eugui E, Wang CC, Allison AC (February 1990). "Synthesis and immunosuppressive activity of some side-chain variants of mycophenolic acid". Journal of Medicinal Chemistry. 33 (2): 833–8. doi:10.1021/jm00164a057. PMID 1967654.
Eugui EM, Allison AC (June 1993). "Immunosuppressive activity of mycophenolate mofetil". Annals of the New York Academy of Sciences. 685 (1): 309–29. Bibcode:1993NYASA.685..309E. doi:10.1111/j.1749-6632.1993.tb35881.x. PMID 8363235. S2CID 9028169.
Allison AC, Eugui EM (February 1996). "Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF)". Clinical Transplantation. 10 (1 Pt 2): 77–84. doi:10.1111/j.1399-0012.1996.tb00651.x. PMID 8680053.
Allison AC, Eugui EM (1993). "The design and development of an immunosuppressive drug, mycophenolate mofetil". Springer Seminars in Immunopathology. 14 (4): 353–80. doi:10.1007/bf00192309. PMID 8322167. S2CID 26433174.
Allison AC, Eugui EM (December 1993). "Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil". Immunological Reviews. 136 (1): 5–28. doi:10.1111/j.1600-065x.1993.tb00652.x. PMID 7907572. S2CID 711727.
Bechstein WO, Suzuki Y, Kawamura T, Jaffee B, Allison A, Hullett DA, et al. (1992). "Low-dose combination therapy of DUP-785 and RS-61443 prolongs cardiac allograft survival in rats". Transplant International. 5 (Suppl 1): S482-3. doi:10.1111/tri.1992.5.s1.482. PMID 14621853. S2CID 222199749.
Kawamura T, Hullett DA, Suzuki Y, Bechstein WO, Allison AM, Sollinger HW (April 1993). "Enhancement of allograft survival by combination RS-61443 and DUP-785 therapy". Transplantation. 55 (4): 691–4, discussion 694–5. doi:10.1097/00007890-199304000-00001. PMID 8475537.
Taylor DO, Ensley RD, Olsen SL, Dunn D, Renlund DG (1994). "Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation". The Journal of Heart and Lung Transplantation. 13 (4): 571–82. PMID 7947873.
van Gelder T, Hesselink DA (May 2015). "Mycophenolate revisited". Transplant International. 28 (5): 508–15. doi:10.1111/tri.12554. PMID 25758949. S2CID 1673466.
Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC (June 2003). "Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil". Archives of Dermatology. 139 (6): 739–42. doi:10.1001/archderm.139.6.739. PMID 12810504.
Diamond MS, Zachariah M, Harris E (December 2002). "Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA". Virology. 304 (2): 211–21. doi:10.1006/viro.2002.1685. PMID 12504563.
Takhampunya R, Ubol S, Houng HS, Cameron CE, Padmanabhan R (July 2006). "Inhibition of dengue virus replication by mycophenolic acid and ribavirin". The Journal of General Virology. 87 (Pt 7): 1947–52. doi:10.1099/vir.0.81655-0. PMID 16760396.
Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, et al. (December 2013). "Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus". The Journal of Infection. 67 (6): 606–16. doi:10.1016/j.jinf.2013.09.029. PMC 7112612. PMID 24096239.
Xiao Y, Huang J, Luo H, Wang J (February 2014). "Mycophenolate mofetil for relapsing-remitting multiple sclerosis". The Cochrane Database of Systematic Reviews. 2014 (2): CD010242. doi:10.1002/14651858.CD010242.pub2. PMC 10875409. PMID 24505016.

ncbi.nlm.nih.gov

Moore RA, Derry S (2006). "Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis". Arthritis Research & Therapy. 8 (6): R182. doi:10.1186/ar2093. PMC 1794528. PMID 17163990.
Singh JA, Hossain A, Kotb A, Wells GA (September 2016). "Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis". Systematic Reviews. 5 (1): 155. doi:10.1186/s13643-016-0328-z. PMC 5020478. PMID 27619512.
Fu R, Ceballos-Picot I, Torres RJ, Larovere LE, Yamada Y, Nguyen KV, et al. (May 2014). "Genotype-phenotype correlations in neurogenetics: Lesch-Nyhan disease as a model disorder". Brain. 137 (Pt 5): 1282–303. doi:10.1093/brain/awt202. PMC 3999711. PMID 23975452.
Regueira TB, Kildegaard KR, Hansen BG, Mortensen UH, Hertweck C, Nielsen J (May 2011). "Molecular basis for mycophenolic acid biosynthesis in Penicillium brevicompactum". Applied and Environmental Microbiology. 77 (9): 3035–43. Bibcode:2011ApEnM..77.3035R. doi:10.1128/AEM.03015-10. PMC 3126426. PMID 21398490.
Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, et al. (December 2013). "Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus". The Journal of Infection. 67 (6): 606–16. doi:10.1016/j.jinf.2013.09.029. PMC 7112612. PMID 24096239.
Xiao Y, Huang J, Luo H, Wang J (February 2014). "Mycophenolate mofetil for relapsing-remitting multiple sclerosis". The Cochrane Database of Systematic Reviews. 2014 (2): CD010242. doi:10.1002/14651858.CD010242.pub2. PMC 10875409. PMID 24505016.

dailymed.nlm.nih.gov

"CellCept- mycophenolate mofetil tablet, film coated CellCept- mycophenolate mofetil capsule CellCept- mycophenolate mofetil hydrochloride injection, powder, lyophilized, for solution CellCept- mycophenolate mofetil powder, for suspension". DailyMed. Archived from the original on 24 October 2020. Retrieved 23 October 2020.
"Myhibbin- mycophenolate mofetil suspension". DailyMed. 7 May 2024. Retrieved 16 June 2024.

psu.edu

citeseerx.ist.psu.edu

D'Cruz DP, Khamashta MA, Hughes GR (February 2007). "Systemic lupus erythematosus". Lancet. 369 (9561): 587–96. CiteSeerX 10.1.1.1008.5428. doi:10.1016/S0140-6736(07)60279-7. PMID 17307106. S2CID 28468112.

roche.com

"CellCept registry data demonstrated superior long-term organ transplant outcomes". Roche.com. F. Hoffmann-La Roche Ltd. Archived from the original on 26 July 2014. Retrieved 23 July 2014.

semanticscholar.org

api.semanticscholar.org

D'Cruz DP, Khamashta MA, Hughes GR (February 2007). "Systemic lupus erythematosus". Lancet. 369 (9561): 587–96. CiteSeerX 10.1.1.1008.5428. doi:10.1016/S0140-6736(07)60279-7. PMID 17307106. S2CID 28468112.
Knight SR, Russell NK, Barcena L, Morris PJ (March 2009). "Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review". Transplantation. 87 (6): 785–94. doi:10.1097/TP.0b013e3181952623. PMID 19300178. S2CID 33596652.
Remuzzi G, Lesti M, Gotti E, Ganeva M, Dimitrov BD, Ene-Iordache B, et al. (2004). "Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial". Lancet. 364 (9433): 503–12. doi:10.1016/S0140-6736(04)16808-6. PMID 15302193. S2CID 22033113.
Fulton B, Markham A (February 1996). "Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation". Drugs. 51 (2): 278–98. doi:10.2165/00003495-199651020-00007. PMID 8808168. S2CID 46954073.
Ransom JT (December 1995). "Mechanism of action of mycophenolate mofetil". Therapeutic Drug Monitoring. 17 (6): 681–4. doi:10.1097/00007691-199512000-00023. PMID 8588241. S2CID 6439393.
Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. (November 2011). "Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis". The New England Journal of Medicine. 365 (20): 1886–95. doi:10.1056/NEJMoa1014460. hdl:20.500.12648/8250. PMID 22087680. S2CID 27689350. Archived from the original on 8 March 2022. Retrieved 25 November 2021.
Zhang W, Ding C, Zheng S (April 2014). "Enteric-coated mycophenolate sodium: an update". International Journal of Clinical Practice. Supplement. 68 (181): 1–3. doi:10.1111/ijcp.12399. PMID 24673712. S2CID 2630344.
Lipsky JJ (November 1996). "Mycophenolate mofetil". Lancet. 348 (9038): 1357–9. doi:10.1016/S0140-6736(96)10310-X. PMID 8918281. S2CID 36837474.
Watts G (2014). "Anthony Clifford Allison". The Lancet. 383 (9925): 1290. doi:10.1016/S0140-6736(14)60635-8. S2CID 54281245.
Allison AC, Kowalski WJ, Muller CD, Eugui EM (November 1993). "Mechanisms of action of mycophenolic acid". Annals of the New York Academy of Sciences. 696 (1): 63–87. Bibcode:1993NYASA.696...63A. doi:10.1111/j.1749-6632.1993.tb17143.x. PMID 7906496. S2CID 34520788.
Eugui EM, Allison AC (June 1993). "Immunosuppressive activity of mycophenolate mofetil". Annals of the New York Academy of Sciences. 685 (1): 309–29. Bibcode:1993NYASA.685..309E. doi:10.1111/j.1749-6632.1993.tb35881.x. PMID 8363235. S2CID 9028169.
Allison AC, Eugui EM (1993). "The design and development of an immunosuppressive drug, mycophenolate mofetil". Springer Seminars in Immunopathology. 14 (4): 353–80. doi:10.1007/bf00192309. PMID 8322167. S2CID 26433174.
Allison AC, Eugui EM (December 1993). "Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil". Immunological Reviews. 136 (1): 5–28. doi:10.1111/j.1600-065x.1993.tb00652.x. PMID 7907572. S2CID 711727.
Bechstein WO, Suzuki Y, Kawamura T, Jaffee B, Allison A, Hullett DA, et al. (1992). "Low-dose combination therapy of DUP-785 and RS-61443 prolongs cardiac allograft survival in rats". Transplant International. 5 (Suppl 1): S482-3. doi:10.1111/tri.1992.5.s1.482. PMID 14621853. S2CID 222199749.
van Gelder T, Hesselink DA (May 2015). "Mycophenolate revisited". Transplant International. 28 (5): 508–15. doi:10.1111/tri.12554. PMID 25758949. S2CID 1673466.

stanford.edu

web.stanford.edu

Donlon DM (15 June 1995). "New Agent to Prevent Kidney Transplant Rejection Now Available". Stanford University. Archived from the original on 27 July 2014. Retrieved 23 July 2014.

tga.gov.au

"Pharmacor mycophenolate, mycocell, alcept (Pharmacor Pty Ltd)". Therapeutic Goods Administration (TGA). 11 November 2022. Archived from the original on 18 March 2023. Retrieved 29 April 2023.

ebs.tga.gov.au

"CellCept" (PDF). TGA eBusiness Services. Roche Products Pty Limited. 13 December 2012. Archived from the original on 8 July 2020. Retrieved 25 February 2014.

unc.edu

cdr.lib.unc.edu

Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. (November 2011). "Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis". The New England Journal of Medicine. 365 (20): 1886–95. doi:10.1056/NEJMoa1014460. hdl:20.500.12648/8250. PMID 22087680. S2CID 27689350. Archived from the original on 8 March 2022. Retrieved 25 November 2021.

web.archive.org

"Mycophenolate mofetil (CellCept) Use During Pregnancy". Drugs.com. 24 January 2020. Archived from the original on 28 October 2019. Retrieved 6 April 2020.
"CellCept (mycophenolate mofetil)". Australian Product Information. 30 November 2021. Archived from the original on 8 January 2023. Retrieved 8 January 2023.
"Pharmacor mycophenolate, mycocell, alcept (Pharmacor Pty Ltd)". Therapeutic Goods Administration (TGA). 11 November 2022. Archived from the original on 18 March 2023. Retrieved 29 April 2023.
"CellCept 1g/5ml powder for oral suspension - Summary of Product Characteristics (SmPC)". (emc). 27 February 2020. Archived from the original on 25 September 2020. Retrieved 22 October 2020.
"Cellcept 250mg Capsules - Summary of Product Characteristics (SmPC)". (emc). 17 June 2020. Archived from the original on 25 September 2020. Retrieved 22 October 2020.
"Cellcept 500mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 25 September 2020. Retrieved 22 October 2020.
"CellCept- mycophenolate mofetil tablet, film coated CellCept- mycophenolate mofetil capsule CellCept- mycophenolate mofetil hydrochloride injection, powder, lyophilized, for solution CellCept- mycophenolate mofetil powder, for suspension". DailyMed. Archived from the original on 24 October 2020. Retrieved 23 October 2020.
"CellCept EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 6 April 2020. Retrieved 6 April 2020.
"CellCept" (PDF). TGA eBusiness Services. Roche Products Pty Limited. 13 December 2012. Archived from the original on 8 July 2020. Retrieved 25 February 2014.
"Mycophenolate Monograph for Professionals". Drugs.com. Archived from the original on 21 April 2020. Retrieved 28 October 2019.
Schiff ER, Maddrey WC, Sorrell MF (2011). Schiff's Diseases of the Liver. John Wiley & Sons. p. PT3219. ISBN 978-1-119-95048-6. Archived from the original on 29 April 2023. Retrieved 23 September 2020.
Laskin AI, Bennett JW, Gadd GM (2001). Advances in Applied Microbiology. Gulf Professional Publishing. p. 236. ISBN 978-0-12-002648-7. Archived from the original on 29 April 2023. Retrieved 23 September 2020.
"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
Harber M (2014). Harber M (ed.). Practical nephrology. Springer. p. 449. ISBN 978-1-4471-5547-8. Archived from the original on 29 April 2023. Retrieved 23 September 2020.
"CellCept, Myfortic (mycophenolate) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Archived from the original on 30 April 2021. Retrieved 9 November 2014.
"Homepage - BNF Publications". www.bnf.org. Archived from the original on 27 April 2021. Retrieved 9 November 2014.
"CellCept (mycophenolate mofetil) August 2009". U.S. Food and Drug Administration. 14 August 2009. Archived from the original on 21 August 2009. Retrieved 21 August 2009.
"CellCept (mycophenolate mofetil) August 2009". U.S. Food and Drug Administration. 14 August 2009. Archived from the original on 21 August 2009. Retrieved 21 August 2009.
"FDA Issues Second CellCept Warning". newsinferno.com. 18 May 2008. Archived from the original on 24 February 2013. Retrieved 26 October 2010.
"MedWatch Safety Alerts for Human Medical Products". fda.gov. May 2008. Archived from the original on 19 October 2010. Retrieved 26 October 2010.
Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. (November 2011). "Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis". The New England Journal of Medicine. 365 (20): 1886–95. doi:10.1056/NEJMoa1014460. hdl:20.500.12648/8250. PMID 22087680. S2CID 27689350. Archived from the original on 8 March 2022. Retrieved 25 November 2021.
Zhang L, Demain AL (2005). Natural Products: Drug Discovery and Therapeutic Medicine. Totowa, N.J.: Humana Press. p. 14. ISBN 978-1-59259-976-9. Archived from the original on 29 April 2023. Retrieved 16 August 2019.
"Risk Evaluation and Mitigation Strategy (REMS) Under Review for CellCept and Myfortic". U.S. Food and Drug Administration. Archived from the original on 8 August 2014. Retrieved 23 July 2014.
Donlon DM (15 June 1995). "New Agent to Prevent Kidney Transplant Rejection Now Available". Stanford University. Archived from the original on 27 July 2014. Retrieved 23 July 2014.
"CellCept registry data demonstrated superior long-term organ transplant outcomes". Roche.com. F. Hoffmann-La Roche Ltd. Archived from the original on 26 July 2014. Retrieved 23 July 2014.